{"SPADE_N_05152": {"Clinical Information": [], "Patent Information": [{"Patent No": "US 2012/0052048 A1", "Patent Link": "http://www.lens.org/lens/patent/US_2012_0052048_A1", "Patent Type": "Patent Application", "Publication Date": "2012-3-1", "Family Info": "CA2751641A1,CN102348460A,EP2393502A2,WO2010090542A2,WO2010090542A3", "Patent Title": "Antibacterial phage, phage peptides and methods of use thereof.", "Abstract": "The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies."}], "Sequence Information": {"SPADE ID": "SPADE_N_05152", "Sequence": "MTIIDYGSKPLNNCSKNELLDIIQSQLENEVKLIKLIERTTKEVEEEKEVPHYKNYISPEKRSYLEGMERVENIVRNFYGFNNE", "Sequence Length": 84, "Peptide Name": "Sequence 149 from Patent US 20120052048", "Source": "Phage F170/08", "Biological Activity": ["Antimicrobial", "Antibacterial"], "Frequent Amino Acids": "ENI", "Absent Amino Acids": "AOUW", "Basic Residues": 13, "Acidic Residues": 16, "Hydrophobic Residues": 32, "Polar Residues": 43, "Positive Residues": 13, "Negative Residues": 16, "Mass": 9996.19, "PI": 5.08, "Net Charge": -3, "Hydrophobicity": -0.83, "Similar Sequences": []}}}